Beck K H, Mohr P, Bleckmann U, Schweer H, Kretschmer V
Department of Transfusion Medicine and Hemostaseology, Klinikum, Philips University, Marburg, Germany.
Semin Thromb Hemost. 1995;21 Suppl 2:32-9. doi: 10.1055/s-0032-1313600.
The mechanism of DDAVP's shortening of acetylsalicylic acid (ASA) prolonged bleeding times was investigated. Sixteen healthy subjects received two dosages of ASA (100 mg) in 12 hours. Twenty four hours after the first ASA application and again after 32 hours DDAVP was administered intravenously (0.4 micrograms/kg). The trial was terminated after 48 hrs. In between, blood samples were drawn and analyzed for the in vivo bleeding time (Simplate time), in vitro bleeding test (IVBT, Thrombostat 4000), von Willebrand factor antigen (vWf:Ag), Ristocetin cofactor activity (vWf R:Co), plasma beta-thromboglobulin (beta-TG), platelet ATP/ADP, platelet aggregation (collagen, ADP, arachidonic acid), and plasma and platelet thromboxane levels. Simplate time (BT) and IVBT showed an excellent inverse correlation with vWf R:Co (r2 BT = 0.97 and r2 IVBT = 0.99, respectively) during the time when DDAVP was administered, suggesting the involvement of plasma vWF in DDAVP's shortening of the bleeding time. The involvement of plasma thromboxane in this mechanism could be excluded. In addition, DDAVP hampered platelet aggregation tests, possibly due to the inhibition of the release reaction (reduced beta-TG in plasma) by a direct interaction with platelets.
研究了去氨加压素缩短乙酰水杨酸(ASA)所致延长出血时间的机制。16名健康受试者在12小时内接受了两剂ASA(100毫克)。首次应用ASA后24小时,以及32小时后再次静脉注射去氨加压素(0.4微克/千克)。48小时后试验结束。在此期间,采集血样并分析体内出血时间(Simplate时间)、体外出血试验(IVBT,Thrombostat 4000)、血管性血友病因子抗原(vWf:Ag)、瑞斯托霉素辅因子活性(vWf R:Co)、血浆β-血小板球蛋白(β-TG)、血小板ATP/ADP、血小板聚集(胶原、ADP、花生四烯酸)以及血浆和血小板血栓素水平。在给予去氨加压素期间,Simplate时间(BT)和IVBT与vWf R:Co呈极好的负相关(r2 BT分别为0.97,r2 IVBT为0.99),提示血浆vWF参与了去氨加压素缩短出血时间的过程。可以排除血浆血栓素参与这一机制。此外,去氨加压素妨碍血小板聚集试验,可能是由于其与血小板直接相互作用抑制了释放反应(血浆中β-TG降低)。